Trial Profile
A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur; Paclitaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms Ahead-G325
- 05 Jun 2018 Updated data from a phase II trial assessing long-term efficacy and safety; results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results assessing the efficacy and safety of apatinib plus chemotherapy in vivo (n=4) and in vitro, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 21 Jan 2017 Results (n=33) evaluating the efficacy and safety of S1/paclitaxel chemotherapy plus apatinib in patients with unresectable gastric cancer, presented at the 2017 Gastrointestinal Cancers Symposium.